Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.

Carneiro, Benedito A; Papadopoulos, Kyriakos P; Strickler, John H; Lassman, Andrew B; Waqar, Saiama N; Chae, Young Kwang; Patel, Jyoti D; Shacham-Shmueli, Einat; Kelly, Karen; Khasraw, Mustafa; Bestvina, Christine M; Merrell, Ryan; Huang, Kevin; Atluri, Harisha; Ansell, Peter; Li, Rachel; Jin, Janet; Anderson, Mark G; Reilly, Edward B; Morrison-Thiele, Gladys; Patel, Kalpesh; Robinson, Randy R; Aristide, Martha R Neagu; Gan, Hui K

doi:10.1093/noajnl/vdac183

Title

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.

Publication Date

2023

Author(s)

Carneiro, Benedito A

Papadopoulos, Kyriakos P

Strickler, John H

Lassman, Andrew B

Waqar, Saiama N

Chae, Young Kwang

Patel, Jyoti D

Shacham-Shmueli, Einat

Kelly, Karen

Khasraw, Mustafa

Bestvina, Christine M

Merrell, Ryan

Huang, Kevin

Atluri, Harisha

Ansell, Peter

Li, Rachel

Jin, Janet

Anderson, Mark G

Reilly, Edward B

Morrison-Thiele, Gladys

Patel, Kalpesh

Robinson, Randy R

Aristide, Martha R Neagu

Gan, Hui K

Subject

EGFR

antibody-drug conjugate

glioblastoma

phase I

serclutamab talirine

Type of document

Journal Article

OrcId

0000-0002-5468-1126

#PLACEHOLDER_PARENT_METADATA_VALUE#

0000-0001-7386-9928

#PLACEHOLDER_PARENT_METADATA_VALUE#

0000-0003-3249-9849

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.1093/noajnl/vdac183

Abstract

Serclutamab talirine (Ser-T, formerly ABBV-321) is an antibody-drug conjugate consisting of an antibody (AM-1-ABT-806) directed against activated epidermal growth factor receptor (EGFR) and a pyrrolobenzodiazepine dimer. We investigated Ser-T monotherapy in a phase I, first-in-human, dose-escalation, and dose-expansion study in patients with advanced solid tumors associated with EGFR overexpression.

Link

link

Citation

Neuro-oncology advances 2023; 5(1):vdac183

Jornal Title

Neuro-oncology advances

ISSN

2632-2498

Austin Health

Files: